Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers

Rosa Polo 1, Xabier García-Albéniz 2, Carolina Terán 4, Miguel Morales 5, David Rial-Crestelo 6, 7, M. Angeles Garcíaño 8, Miguel García del Toro 9, César Hita 10, Juan Luis Gómez-Sirvent 11, Luis Buzon 12, Alberto Díaz de Santiago 13, Jose Pérez Arellano 14, Jesus Sanz 7, 15, Pablo Bachiller 16, Elisa Martínez Alfaro 17, Vicente Díaz-Brito 18, Mar Masía 7, 19, Alicia Hernández-Torres 20, Jose M. Guerra 21, Jesús Santos 22, Piedad Arazo 23, Leopoldo Muñoz 24, Jose Ramon Arribas 7, 25, Pablo Martínez de Salazar 26, Santiago Moreno 7, 27, Miguel A. Hernán 2, 28, 1, Julia Del Amo 1, 7, 1, * on behalf of EPICOS 1

1) Division for HIV, STI, Viral Hepatitis and TB Control, Ministry of Health, Madrid, Spain
2) CAUSAlab, Harvard T.H. Chan School of Public Health, Boston, MA, USA
3) RTI Health Solutions, Barcelona, Spain
4) Facultad de Medicina Universidad Mayor, Real y Pontificia de San Francisco Xavier de Chuquisaca, Hospital Santa Bárbara, Sucre, Bolivia
5) Hospital Militar Dr. Carlos Arvelo, Caracas, Venezuela
6) Hospital Doce de Octubre, Madrid, Spain
7) CIBER de Enfermedades Infecciosas, Institute of Health Carlos III, Madrid, Spain
8) Hospital Nuestra Señora de Sonsoles, Avila, Spain
9) Hospital General de Valencia, Valencia, Spain
10) Hospital de Torrejón, Madrid, Spain
11) Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
12) Hospital Universitario de Burgos, Burgos, Spain
13) Hospital Universitario Puerta de Hierro, Madrid, Spain
14) Hospital Universitario Insular de Gran Canaria, Gran Canaria, Spain
15) Hospital Universitario de la Princesa, Madrid, Spain
16) Hospital General de Segovia, Segovia, Spain
17) Complejo Hospitalario Universitario de Albacete, Albacete, Spain
18) Parc Sanitari Sant Joan de Déu, Barcelona, Spain
19) Hospital General Universitario de Ejea, Alicante, Spain
20) Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
21) Hospital Universitario de León, León, Spain
22) Hospital Universitario Virgen de la Victoria de Málaga, Málaga, Spain
23) Hospital Universitario Miguel Servet, Zaragoza, Spain
24) Complejo Hospitalario Universitario de Granada, Granada, Spain
25) Hospital Universitario La Paz, IDIPMZ, Madrid, Spain
26) Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
27) Hospital Universitario Ramón y Cajal, Madrid, Spain
28) Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA

* Corresponding author: Julia Del Amo, Division for HIV, STI, Viral Hepatitis and TB Control, Ministry of Health, Madrid, Spain.
E-mail address: jamo@sanidad.gob.es (J. Del Amo).

1 Miguel A. Hernán and Julia Del Amo are co-senior authors.
2 Members of collaborators are listed in appendix section.

https://doi.org/10.1016/j.cmi.2022.07.006
1988-743X/© 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
**Introduction**

Drug repurposing for prophylaxis against COVID-19 started early in the pandemic [1]. Based largely on *in vitro* evidence, randomized trials of hydroxychloroquine (HCQ) as pre-exposure prophylaxis were among the earliest to be launched [1–5]. However, these trials were small and resulted in imprecise effect estimates [2–5]. Tenofovir disoproxil fumarate (TDF) was another candidate for repurposing based on epidemiological data [6,7], *in vitro* and *in vivo* studies [8–13], and its high bioavailability in many tissues [14–16]. However, no randomized trials of TDF for pre-exposure prophylaxis have been completed.

Both HCQ and TDF are generic drugs widely prescribed worldwide with a well-documented safety record [17–19]. HCQ has been used as treatment and prophylaxis of malaria. TDF, in combination with emtricitabine (FTC), has been used for the treatment and prophylaxis of HIV infection. Despite their potential for COVID-19 prophylaxis, these safe and inexpensive drugs have not been studied in randomized trials (TDF) or the randomized trials have been relatively small (HCQ).

We carried out a double-blind placebo-controlled randomized trial to assess the effect of daily HCQ or TDF/FTC, and of their combination, during 12 weeks as pre-exposure prophylaxis against COVID-19 in healthcare workers.

**Methods**

EPICOS (NCT04334928, EudraCT number 2020-001385-11) was a multicentre, double-blind, placebo-controlled randomized trial to study the effect of TDF/FTC and HCQ as pre-exposure prophylaxis for symptomatic COVID-19 among healthcare workers in Spain, Bolivia, and Venezuela. The trial was designed to recruit 4000 individuals. Assuming a 5% to 10% risk of symptomatic COVID-19 in the placebo group and less than half in the treatment groups, this sample size ensured that the 95% CIs would only include effect values compatible with treatment benefit. However, the start of the vaccination campaign and other factors limited recruitment to 907 participants.

Recruitment into the trial was actively promoted in Spain through regional health authorities and the Ministry of Health, and in Latin America through Esther (Ensemble de Solidarité Thérapeutique Hospitalière En Reseau). Healthcare workers were approached individually and collectively through promotional in-hospital sessions, mailings, and hospital-wide advertisements, and were screened for eligibility after providing informed consent. A mobile phone app was developed for electronic monitoring, weekly reminders of adherence, and side-effects reporting.

**Eligibility criteria**

Healthcare workers aged 18 to 70 years were eligible if they did not have a prior diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, did not have symptoms compatible with SARS-CoV-2 infection, had a negative IgM/IgG test for SARS-CoV-2, had negative HIV and (for women) pregnancy tests, a normal electrocardiogram, and no history of QT interval prolongation, maculopathy, impaired renal function, or immunosuppressive or hematologic conditions. Because women comprised the majority of healthcare workers, we ensured 40% of individuals screened for eligibility were males. Recruitment started in April 2020 in Spain, October 2020 in Bolivia, and March 2021 in Venezuela (Supplementary Fig. 1). The study ended on 30 May 2021.

**Randomization and masking**

Eligible individuals were randomly assigned to one of four treatment groups: TDF/FTC plus HCQ, TDF/FTC plus HCQ placebo, HCQ plus TDF/FTC placebo and TDF/FTC placebo plus HCQ placebo. Randomization was performed with random permuted blocks using a block size of four. The randomization list was computer-generated by a biostatistician with no clinical involvement in the study and before the study started. Medication was prepared accordingly by an external provider, labelled with a unique consecutive number and assigned in chronological order according to the date of treatment initiation in each centre. Investigators, participants, and data analysts were unaware of their treatment assignment. The allocation concealment was preserved by using identical treatment and
placebo tablets. The TDF/FTC placebo was provided by the TDF/FTC manufacturing company who donated the drug and the HCQ was designed ad-hoc for the purpose of this study.

TDF/FTC was administered as a single pill with 245mg of TDF and 200 mg of FTC once daily). HCQ was administered as 200 mg once daily, the minimum dose to reach adequate tissue distribution [20]. Participants received treatment for 12 weeks (or until a SARS-CoV-2 infection was diagnosed), irrespective of symptoms, or the administrative end of the study, whichever occurred first.

Outcomes

The primary outcome was symptomatic COVID-19, defined as the presence of SARS-CoV-2 infection confirmed by a polymerase chain reaction (PCR) test plus any of the following symptoms: general malaise, fever, cough, joint pain, or breathing difficulty. PCR-confirmed asymptomatic SARS-CoV-2 infection was a secondary outcome. Other secondary outcomes were duration of symptoms and severity, though the later could not be studied. We also studied the outcome “any (symptomatic or asymptomatic) COVID-19 infection”, which had not been pre-specified in the study protocol.

Adherence (number of missed pills) and adverse events were ascertained in each monthly visit and weekly through app reminders. Adverse events were classified as mild (easily tolerated), moderate (interference with normal activities), or severe (in-capacitating, with inability to perform normal activities). Regardless of severity, adverse events were classified as serious if they required hospitalization, prolonged an existing hospitalization, or led to major or permanent disability.

Follow-up

Participants attended three monthly visits after randomization. In each visit, they were evaluated for the presence of adverse events, adherence, received standard laboratory tests, IgM/IgG antibody test for SARS-CoV-2, and an electrocardiogram if necessary. A PCR test was performed if the IgM/IgG antibody test was positive or if symptoms were present. A fourth monthly visit was scheduled for the evaluation of adverse events only.

The trial was stopped after recommendations to vaccinate healthcare workers were issued in each country. The decision was made by the trial investigators with the agreement of the Data Safety Monitoring Board.

Statistical analysis

We used the Kaplan-Meier estimator to obtain outcome risks over 14 weeks of follow-up in each treatment group (over 95% of participants had attended their third monthly visit by 14 weeks after randomization). We compared group-specific risks via differences and ratios with the placebo-only group as the reference. Participants were censored if/when they were lost to follow-up. In post hoc analyses, we compared the risk between the two groups containing HCQ and the two groups not containing HCQ, and between the two groups containing TDF/FTC and the two groups not containing TDF/FTC. We calculated 95% CIs using the percentile bootstrap method with 500 repetitions. In sensitivity analyses, we used a Cox model to estimate hazard ratios.

This study was approved by the institutional review boards of University Hospital de La Princesa, Madrid, Spain, Servicio Departamental de Salud de Chuquisaca in Bolivia, and Instituto Nacional de Higiene "Rafael Rangel" in Venezuela. An independent medical monitor and a data safety monitoring board provided oversight of safety and efficacy.

Results

Of 1002 individuals screened for eligibility, 926 (92.4%) were eligible. The main reason for ineligibility was a previous COVID-19 diagnosis or compatible symptoms (Fig. 1). Nineteen individuals withdrew or were lost to follow-up before treatment assignment. Of 907 randomized individuals, 220 were assigned to the TDF/FTC plus HCQ group (12 did not start treatment), 231 to the TDF/FTC placebo plus HCQ group (7 did not start treatment), 233 to the TDF/FTC plus HCQ placebo group (12 did not start treatment), and 223 to the double placebo group (12 did not start treatment). Of 696 individuals who completed the scheduled follow-up, 668 completed treatment as indicated in the protocol. The Supplementary materials, Tables S1 and S2, show the reasons for early termination of treatment and incomplete follow-up, respectively, by treatment group.

Baseline characteristics of the 907 participants are summarized in Table 1 and the Supplementary material, Table S3. Median age was 38 years (range 18 to 68 years) and 62.5% (567/907) were female. Most participants worked at inpatient care facilities (62.3%; 565/907) and the most frequent occupation was physician (30.8%; 279/907), 64.2% (582/907) of participants were recruited in Spain, 22.3% (202/907) in Bolivia, and 13.6% (123/907) in Venezuela. Comorbidities were rare.

Fig. 2(a) shows the cumulative risk of asymptomatic COVID-19 by treatment group. There were 14 cases: 3 in each group with active treatment and 5 in the placebo-only group. All cases had mild symptoms, with variable duration, that did not require hospitalization (see Supplementary material, Table S4). Compared with the placebo-only group, the 14-week risk ratio (95% CI) of asymptomatic COVID-19 was 0.39 (0.00–1.98) for TDF + HCQ, 0.34 (0.00–2.06) for TDF, and 0.49 (0.00–2.29) for HCQ (Table 2).

The 14-week risk ratio (95% CI) of asymptomatic COVID-19 was 0.68 (0.10–2.04) for the groups assigned to HCQ compared with the two groups not assigned to HCQ (see Supplementary materials, Table S5 and Fig. S2), and 0.49 (0.09–1.70) for the groups assigned to TDF/FTC compared with the two groups not assigned to TDF/FTC (see Supplementary materials, Table S6 and Fig. S3).

Fig. 2(b) shows the cumulative risk of asymptomatic COVID-19 by treatment group. There were 63 cases: 10 in the TDF/FTC + HC group, 17 in the TDF/FTC group, 18 in the HCQ group, and 17 in the placebo only group. Compared with the placebo only group, the 14-week risk ratio (95% CI) of symptomatic COVID-19 was 0.54 (0.21–1.19) for TDF + HCQ, 0.83 (0.45–1.66) for TDF, and 0.89 (0.49–1.91) for HCQ (Table 2).

The 14-week risk ratio (95% CI) of symptomatic COVID-19 was 0.79 (0.47–1.33) for the groups assigned to HCQ compared with the groups not assigned to HCQ (see Supplementary materials, Table S5 and Fig. S2), and 0.74 (0.43–1.21) for the groups assigned to TDF/FTC compared with the groups not assigned to TDF/FTC (see Supplementary material, Table S6 and Fig. S3).

Fig. 2(c) shows the cumulative risk of any COVID-19 diagnosis by treatment group. There were 77 cases: 13 in the TDF/FTC + HC group, 20 in the TDF/FTC group, 21 in the HCQ group, and 23 in the placebo only group. Compared with the placebo only group, the 14-week risk ratio (95% CI) of any COVID-19 diagnosis was 0.51 (0.21–1.00) for TDF + HCQ, 0.81 (0.44–1.49) for TDF, and 0.73 (0.41–1.38) for HCQ (Table 2).

The 14-week risk ratio (95% CI) of any COVID-19 diagnosis was 0.78 (0.49–1.23) for the groups assigned to HCQ compared with the groups not assigned to HCQ (see Supplementary materials, Table S5 and Fig. S2), and 0.70 (0.43–1.10) for the groups assigned to TDF/FTC compared with the groups not assigned to TDF/FTC (see Supplementary materials, Table S6 and Fig. S3).
The corresponding hazard ratios were similar (see Supplementary materials, Table S7).

The proportion of individuals with adverse events was 45.0% (99/220) in the TDF/FTC + HCQ group, 41.2% (96/233) in the TDF/FTC group, 36.4% (84/231) in the HCQ group, and 36.8% (82/223) in the double placebo group. Most were mild and of gastrointestinal nature (Table 3). There were five serious adverse events: 4 in the placebo only group (hospital admission because of a bleeding

![Flowchart of participants, EPICOS randomized trial.](image)

**Table 1**
Baseline characteristics of 907 participants, EPICOS randomized trial

| Characteristic                      | TDF/FTC + HCQ (n = 220) | TDF/FTC (n = 233) | HCQ (n = 231) | Placebo (n = 223) |
|------------------------------------|-------------------------|-------------------|---------------|-------------------|
| **Sex, n (%)**                     |                         |                   |               |                   |
| Male                               | 85 (38.6)               | 93 (39.9)         | 82 (35.5)     | 80 (35.9)         |
| Female                             | 135 (61.4)              | 140 (60.1)        | 149 (64.5)    | 143 (64.1)        |
| **Age (y), median (range)**        | 38.0 (18.0, 65.0)       | 39.0 (18.0, 68.0) | 38.0 (18.0, 65.0) | 38.0 (18.0, 65.0) |
| **Occupation, n (%)**              |                         |                   |               |                   |
| Physician                          | 71 (32.3)               | 68 (29.2%)        | 74 (32.0%)    | 66 (29.6%)        |
| Nurse                              | 63 (28.6)               | 77 (33.0%)        | 67 (29.0%)    | 72 (32.3%)        |
| Medical student on clinical rotation | 59 (26.8)              | 58 (24.9%)        | 59 (25.5%)    | 53 (23.8%)        |
| Other, with direct patient contact | 13 (5.9)                | 13 (5.6)          | 11 (4.8)      | 11 (4.9)          |
| Other, without direct patient contact | 13 (5.9)               | 10 (4.3)          | 15 (6.5)      | 18 (8.1)          |
| Unknown                            | 1 (0.5)                 | 7 (3.0)           | 5 (2.2)       | 3 (1.3)           |
| **Comorbidities, n (%)**           |                         |                   |               |                   |
| Cardiac disease                    | 3 (1.4)                 | 0                 | 1 (0.4)       | 2 (0.9)           |
| Hypertension                       | 17 (7.7)                | 15 (6.4)          | 4 (1.7)       | 19 (8.5)          |
| Pulmonary disease                  | 0                       | 0                 | 0             | 0                 |
| Asthma                             | 17 (7.7)                | 8 (3.4)           | 20 (8.7)      | 9 (4.0)           |
| Neoplasia                          | 4 (1.8)                 | 4 (1.7)           | 2 (0.9)       | 1 (0.4)           |
| Diabetes                           | 4 (1.8)                 | 3 (1.3)           | 1 (0.4)       | 3 (1.3)           |
| Autoimmune disease                 | 5 (2.3)                 | 7 (3.0)           | 4 (1.7)       | 2 (0.9)           |
| **Country, n (%)**                 |                         |                   |               |                   |
| Spain                              | 139 (63.2)              | 151 (64.8)        | 148 (64.1)    | 144 (64.6)        |
| Venezuela                          | 31 (14.1)               | 31 (13.3)         | 32 (13.9)     | 29 (13.0)         |
| Bolivia                            | 50 (22.7)               | 51 (21.9)         | 51 (22.1)     | 50 (22.4)         |

HCQ, hydroxychloroquine; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate.
uterine myoma, hospital admission because of smoke inhalation from a workplace fire, an episode of dizziness and bradypsiquia, and an episode of jaundice and vomiting) and 1 in the TDF/FTC group (retinal detachment).

**Discussion**

EPICOS, a double-blind, placebo-controlled randomized trial, evaluated the effect of treatment with HCQ and TDF/FTC, alone or in combination, as pre-exposure prophylaxis for COVID-19 among healthcare workers. Because the trial recruited approximately a quarter of the intended number of participants, the effect estimates were imprecise: compared with placebo, the risk of symptomatic COVID-19 was lower in the groups assigned to HCQ or TDF/FTC, but effects between a 2-fold risk increase and perfect protection were highly compatible with the data. For any (symptomatic or asymptomatic) COVID-19, the risk in the group assigned to combined HCQ plus TDF/FTC was half the risk in the group assigned to placebo only, and effects between a 79% reduction in risk and no reduction in risk were highly compatible with the data.

HCQ and TDF/FTC were safe, with mostly mild adverse events of gastrointestinal nature, which is consistent with the well-established safety record of both drugs [17–19].

Several placebo-controlled randomized trials have studied HCQ at different doses as pre-exposure prophylaxis for (mostly non-severe) COVID-19 in healthcare workers [2,4,5]. Like EPICOS, five of these trials could not achieve their intended sample size [4,5], partly because potential participants were averse to receive HCQ after poorly conducted observational studies (later retracted) [21] suggested HCQ was not safe, and the “nonsignificant” findings of small randomized trials for prophylaxis were misinterpreted as lack of a beneficial effect. However, a meta-analysis of randomized trials found of pre-exposure prophylaxis estimated a risk ratio of COVID-19 of 0.72 (95% CI, 0.58–0.90) for HCQ compared with no HCQ [3]. The largest trial included in the meta-analysis found similar estimates: a COVID-19 hazard ratio of 0.73 (95% CI, 0.48–1.09) for HCQ vs. placebo after 12 weeks of follow-up in a trial with 1483 participants [5], a COVID-19 OR of 0.75 (95% CI, 0.49–1.15) for HCQ vs. placebo after 29 days follow-up in the HERO-HCQ trial with 1359 participants [4], and relative risk of 0.70 (95% CI, 0.44–0.97) for HCQ vs. ascorbic acid after 42 days of follow-up in a cluster randomized trial of 1051 participants [22]. When taken altogether with the findings from EPICOS, the evidence cannot rule out the possibility that prophylaxis with HCQ offers a modest protection against COVID-19 [3].

No previous randomized trials had studied TDF/FTC as pre-exposure prophylaxis for COVID-19. However, several observational studies have found a lower risk of COVID-19 diagnosis or of hospitalization among individuals who use TDF/FTC compared with those who do not [6,7,23–25]. A study among people with HIV in Spain reported lower risk of COVID-19 hospitalization among individuals treated with TDF/FTC compared with those treated with other antiretrovirals [6,7]. However, the estimates were not adjusted for the potentially different clinical characteristics of individuals receiving each treatment. A second study in over 50,000 persons with HIV and adequate virological control, which adjusted for comorbidities and other factors, also found a lower risk ratio of COVID-19 hospitalization for TDF/FTC compared with TAF (Tenofovir Alafenamide)/FTC. Adjusted and unadjusted estimates were similar [24].

A lower risk of COVID-19 hospitalization or death was also found among HIV-positive individuals who used TDF/FTC for HIV treatment in South Africa [23] and among individuals who used TDF for the treatment of hepatitis B infection [25]. Also, in a study of ferrets infected with SARS-CoV-2, the group treated with TDF/FTC group had lower clinical scores and a shorter duration of symptoms [26]. A phase 2 randomized trial in 60 outpatients with early COVID-19 found reductions in nasopharyngeal shedding of SARS-CoV-2 after initiation of TDF/FTC [27]. On the other hand, a recent in vitro study report could not detect substantial activity of TDF/FTC against SARS-CoV-2 [28].

Even if HCQ and TDF/FTC were effective as pre-exposure prophylaxis for COVID-19, vaccines are a better approach to prevention.
when available, at least for the variants studied so far and for immunocompetent persons. The efficacy of vaccines seems to be reduced in immunocompromised patients who are in need of other prophylactic strategies [29]. The predominant variants differed by country and period of study [30]. The effectiveness of antivirals, unlike that of monoclonal antibodies, is not expected to vary substantially across variants that differ in surface antigens.

A timelier question is whether HCQ and TDF/FTC could be used for early treatment of COVID-19 in non-hospitalized patients. The question has already been answered for HCQ [31] but not for TDF/FTC, a generic and inexpensive drug combination with the potential for massive worldwide production, and for which the available evidence supports the need for therapeutic trials.

In summary, we conducted a randomized, double-blind, placebo-controlled clinical trial in 907 healthcare workers to compare the risk of COVID-19 after pre-exposure prophylaxis with HCQ and TDF/FTC. Because recruitment had to be ended prematurely, effect estimates were unstable and do not allow to draw definite

| Table 2 |
| --- |
| Estimated 14-week risks of symptomatic, asymptomatic, and any COVID-19 diagnosis by treatment group, EPICOS randomized trial |

| Symptomatic COVID-19 | Cases/n | 14-week risk % (95% CI) | Risk difference % (95% CI) | Risk ratio (95% CI) |
| --- | --- | --- | --- | --- |
| TDF/FTC + HCQ | 3/220 | 1.10 (0.00–2.55) | -1.70 (-4.41–1.09) | 0.39 (0.00–1.98) |
| TDF/FTC | 3/233 | 0.94 (0.00–2.63) | -1.85 (-4.43–1.16) | 0.34 (0.00–2.06) |
| HCQ | 3/231 | 1.37 (0.00–3.12) | -1.42 (-4.48–1.34) | 0.49 (0.00–2.29) |
| Placebo | 5/223 | 2.79 (0.60–5.22) | Reference | Reference |
| Asymptomatic COVID-19 | --- | --- | --- | --- |
| TDF/FTC + HCQ | 10/220 | 5.51 (2.25–9.04) | -4.61 (-10.4–1.30) | 0.54 (0.21–1.19) |
| TDF/FTC | 17/233 | 8.44 (4.70–12.6) | -1.68 (-7.72–4.26) | 0.83 (0.45–1.66) |
| HCQ | 18/231 | 9.01 (5.37–13.3) | -1.11 (-7.06–4.56) | 0.89 (0.49–1.91) |
| Placebo | 18/223 | 10.1 (5.49–14.5) | Reference | Reference |
| Any COVID-19 | --- | --- | --- | --- |
| TDF/FTC + HCQ | 13/220 | 6.56 (2.75–10.27) | -6.17 (-12.32–0.01) | 0.51 (0.21–1.00) |
| TDF/FTC | 20/233 | 9.31 (5.79–13.69) | -3.42 (-9.61–3.32) | 0.81 (0.45–1.66) |
| HCQ | 21/231 | 10.35 (6.23–14.82) | -2.39 (-7.06–4.38) | 0.73 (0.41–1.38) |
| Placebo | 23/223 | 12.74 (7.92–17.44) | Reference | Reference |

HCQ, hydroxychloroquine; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate.

Table 3

| Severity of adverse event | TDF/FTC + HCQ (n = 220) | TDF/FTC (n = 233) | HCQ (n = 231) | Placebo (n = 223) |
| --- | --- | --- | --- | --- |
| Gastrointestinal disorders | 68 (30.9) | 73 (31.3) | 56 (24.2) | 56 (24.2) |
| Blood and lymphatic system disorders | 1 (0.5) | 0 | 0 | 0 |
| Cardiac disorders | 4 (1.8) | 1 (0.4) | 0 | 0 |
| Ear and labyrinth disorders | 2 (0.9) | 0 | 0 | 0 |
| Eye disorders | 1 (0.5) | 1 (0.4) | 0 | 0 |
| General disorders | 23 (10.5) | 26 (11.2) | 23 (10.0) | 21 (9.4) |
| Immune system disorder | 0 | 1 (0.4) | 0 | 0 |
| Infections | 4 (1.8) | 1 (0.4) | 0 | 0 |
| Injuries | 2 (0.9) | 1 (0.4) | 0 | 0 |
| Musculoskeletal/connective tissue disorders | 9 (4.1) | 9 (3.9) | 6 (2.6) | 6 (2.6) |
| Nervous system disorders | 22 (10.0) | 31 (13.3) | 26 (11.3) | 19 (8.5) |
| Psychiatric disorders | 3 (1.4) | 2 (0.9) | 0 | 0 |
| Reproductive disorders | 1 (0.5) | 1 (0.4) | 0 | 0 |
| Skin disorders | 16 (7.3) | 6 (2.6) | 6 (2.6) | 4 (1.8) |
| Vascular disorders | 0 | 1 (0.4) | 3 (1.3) | 3 (1.3) |

More than one adverse event per participant could occur. Data are presented as n (%).

Abbreviations: HCQ, hydroxychloroquine; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate.

*a* See supplementary methods for a list of the observed adverse events in each system organ class.
conclusions. Our findings are compatible with both benefit and harm of pre-exposure prophylaxis with TDF/FTC and HCQ, alone or in combination, compared with placebo.

**Transparency declaration**

Miguel del Toro has received payment for lectures, presentations, speakers bureaus, manuscript writing or educational events from Viiv Healthcare, Gilead Sciences, and Janssen. José Ramón Arribas has received consulting fees from GSK, MSD, Serono, Lilly, Roche, Pfizer, Gilead and payment for lectures, presentations, speakers bureaus, manuscript writing, or educational events from MSD. Miguel A. Hernán has received consultancy fees from Pro- Publica and Cytel. All authors submitted a COI form to the ESCMID guidelines manager.

EPICOS was sponsored by the Ministry of Health of Spain and supported by research grant COV20/01112, Fondo COVID-19, Instituto de Salud Carlos III, Madrid, Spain. TDF/FTC and TDF/FTC placebos were donated by Gilead Sciences, hydroxychloroquine by Gebro Pharma, hydroxychloroquine placebo by Laboratorios Farmacéuticos Rovi, support for medication packing by Laboratorios Alcalá Farma, and rapid HIV tests by Abbott Laboratories.

**Author contributions**

RP, XGA, PMS, SM, MAH, and JDA designed the study and prepared the protocol. RP and JDA coordinated the project and supervised field work in Spain and Latin America. All authors were involved in the data collection across centres. Data analysis was done by XGA and MAH. All authors were involved in the interpretation of findings and writing of the manuscript, led by MAH and JDA. The corresponding authors had full access to all the data in the study. All authors have read and approved the final manuscript.

**APPENDIX. EPICOS RESEARCH TEAM**

The EPICOS randomized trial was sponsored by the Ministry of Health of Spain.

**EPICOS investigator team**

Julia del amo (principal investigator), Ministry of Health, Madrid, Spain.

Rosa Polo, Ministry of Health, Madrid, Spain.

Santiago Moreno, Hospital Ramón y Cajal, Madrid, Spain.

Juan Berenguer, Hospital Gregorio Marañón, Madrid, Spain.

Esteban Martínez, hospital clinic, Barcelona, Spain.

Miguel Hernán, CAUSA/Ab and Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Pablo Martínez de Salazar, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Xabier García de Albéniz, RTI Health Solutions, Barcelona, Spain.

**Collaborators.**

Marieta Iradier, Fundación Estatal, Salud, Infancia y Bienestar Social.

Inma Jarrín, Institute of Health Carlos III, National Center for Epidemiology.

**Data safety monitoring board.**

Javier Zamora, Hospital Ramón y Cajal, Madrid, Spain.

Antonio Rivero, Hospital Reina Sofía, Córdoba, Spain.

Clara Menéndez, IS Global, Barcelona, Spain.

**Contract research organization**

Enrique Conde and José Montes, Efficce Research, Madrid, Spain.

**Participating hospitals**

Bolivia.

- Facultad de Medicina Universidad Mayor, Real y Pontificia de San Francisco Xavier de Chuquisaca - Hospital Santa Bárbara, Bolivia. PI: Carolina Terán. Co-investigators: Bettsy Flores, María Elena Choque, Jhacelin Peñaranda, Gladys Gorena, Marliz Herrera, Marcela Farfán, David Moya, Jhony Camacho, Jovanna Ordonez, José Mayora, Brayan Farfán

Venezuela.

- Hospital Militar Dr. Carlos Arvelo, Centro Clínico María Edelmira Araujo, Instituto Falconiano de Emergencias Médicas, Venezuela. PI: Miguel Morales. Co-investigators: Maryelis Benítez, Rosa Bolaños, Jesús Colina

Spain

- Hospital Doce de Octubre, Madrid. Co-investigators: Federico Pulido, Rafael Rubio, Othilia Bisbal, María de Lagaré, Cristina Epañza, Cristina Lillo-Díaz, Raúl Martínez

- Hospital Nuestra Señora de Sonsoles, Ávila. Co-investigators: Miguel Sebastián Pedromendoza, César de la Hoz, Demetrio Sánchez, Ana Cristina Antoli, Carmen Grande, Dulce María Astudillo

- Hospital General de Valencia. PI: Miguel Gaita Delorto. Co-investigators: Jose Ignacio chirivella

- Hospital de Torrejón, Madrid. PI: César Hita. Co-investigators: María Carmen Montero, Juan Ruiz.

- Hospital Universitario de Tenerife. Canarias. Co-investigators: Mª María Alonso, Mª Remedios Alemán, Ana Mª López, Dácil García, Ricardo Pelazas.

- Hospital Universitario de Burgos. Co-investigators: Pablo González Recio.

- Hospital Puerta de Hierro, Madrid. Co-investigators: Fernando Martínez-Vera, Alejandro Muñoz, Sara De la Fuente, Ana Muñoz, José Manuel Vázquez

- Hospital Universitario Insular de Gran Canaria. Co-investigators: Cristina Carranza, Michele Hernández, Nieves Jañén, Carmen Lavilla, Elena Pisos, Laura Suárez

- Hospital La Princesa, Madrid. Co-investigators: Ignacio de los Santos, Lucio García-Fraile, Ángela Gutiérrez, Azucena Bautista

- Hospital General de Segovia. Co-investigators: Sara Muñoz, José María Alonso de los Santos, Eva María Ferreira, Ana Carrero.

- Complejo Hospitalario Universitario de Albacete. Co-investigators: Fernando Mateos, José Javier Blanch, Julian Eloy Solis García

- Parc Sanitari Sant Joan de Déu. Sant Boi del Llobregat, Barcelona. Co-investigators: Montserrat Sannmarti, Raquel Gómez, Encarna Moreno, María Carmen Álvarez

- Hospital General Universitario de Elche. Co-investigators: Javier García-Abellán, Félix Gutiérrez, Sergio Padilla, Gabriel Esteañ

- Hospital Clínico Universitario Virgen de la Arrixaca. Murcia. Co-investigators: Encarnación Moral, Sonia Marín, Aychel Elena Roura, Ana Pareja

- Hospital Universitario de León. Co-investigators: Manuel Martín Regidor, Esperanza Gutiérrez, Luis Jorge Valdivia, Patricia Capón

- Hospital Universitario Virgen de la Victoria de Málaga. Co-investigators: Rosario Palacios, Cristina Gomez-Ayerbe, Eva Cabrera César, Alejandro Galán Romero

- Hospital Universitario Miguel Servet. Zaragoza. Co-investigators: Álvaro Cecilio, Rosa Fennell

- Hospital Clínico San Cecilio (Complejo Hospitalario Universitario de Granada). Co-investigators: José Peregrina, Francisco Anguita, Laura Martín

- Hospital Universitario Ramón y Cajal. Madrid. PI: Fernando Dronda. Co-investigators: Johannes Hæmmerle, Clara Crespillo

- Hospital Arnau de Vilanova — Llíria. Valencia. PI: Juan Flores. Co-investigators: Lidia Castellano
Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.climic.2022.07.006.

References

[1] Davis JS, Ferreira D, Denholm JT, Tong SY. Clinical trials for the prevention and treatment of COVID-19: current state of play. Med J Aust 2020;213:86–93. https://doi.org/10.5694/mja2.50673.

[2] Abella BS, Jolivettk ES, Biney BT, Ugal JE, Hyman MC, Frank I, et al. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial. JAMA Intern Med 2021;181:195–202. https://doi.org/10.1001/jamainternmed.2020.5366.

[3] García-Albeniz X, Del Amo J, Polo R, Morales-Aсанcio JM, Hernán MA. Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. Eur J Epidemiol 2022:1–8. https://doi.org/10.1007/s10654-022-09810-4.

[4] Naggie S, Milstone A, Castro M, Collins SP, Seetha L, Anderson DJ, et al. Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial (HERO-HCQ). medRxiv 2021. https://doi.org/10.1101/2021.08.19.21262275.

[5] Rajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pacht KA, Axelrod ML, et al. Hydroxychloroquine as pre-exposure prophylaxis for coronavirus disease 2019 (COVID-19) in healthcare workers: a randomized trial. Clin Infect Dis 2021;72:e835–43. https://doi.org/10.1093/cid/ciaa1571.

[6] Del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arríbas JR, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med 2020;173:536–41. https://doi.org/10.7326/M20-3689.

[7] Del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arríbas JR, et al. Antiretroviral and risk of COVID-19 diagnosis and hospitalization in HIV-positive persons. Epidemiology 2020;31:49–51. https://doi.org/10.1097/ede.0000000000001235.

[8] Chien M, Anderson TK, Jockusch S, Tao C, Li X, Kumar S, et al. Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. J Proteome Res 2020;19:4960–7. https://doi.org/10.1021/acs.jproteome.0c00392.

[9] Clososki GC, Soldí RA, da Silva RM, Guaratini T, Lopes JN, Pereira PR, et al. Tamiflu disopropyl fumarate: new chemical developments and encouraging in vitro biological results for SARS-CoV-2. J Braz Chem Soc 2020;31:1552–6. https://doi.org/10.21577/1013-5053.20200106.

[10] Copertino DC, Casado Lima BC, Duarte RRR, Powell TR, Ormsby CE, Wilkin T, et al. Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. J Biomol Struct Dyn 2021:1–14. https://doi.org/10.1080/07391102.2019.1911044.

[11] Efthymiou AA, Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent DNA polymerase (RDDP): a molecular docking study. Life Sci 2020;253:117592. https://doi.org/10.1016/j.lfs.2020.117592.

[12] Jockusch S, Tao C, Li X, Anderson TK, Chien M, Kumar S, et al. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Antivir Res 2020:180:104857. https://doi.org/10.1016/j.antiviral.2020.104857.

[13] Zanella I, Zizzoli D, Castelli F, Quiros-Roldán E. Tenofovir, another inexpensive, well-known and widely available old drug repurposed for SARS-CoV-2 infection. Pharmaceuticals (Basel) 2021;14:454. https://doi.org/10.3390/ph14050545.

[14] Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and entecavir in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011;3:1312e4. https://doi.org/10.1126/scitranslmed.3003174.

[15] Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, et al. Intracellular tenofovir and entecavir anabolites in genital, rectal, and blood compartments from first dose to steady state. AIDS Res Hum Retroviruses 2016;32:981–91. https://doi.org/10.1089/aid.2016.0008.

[16] Twigg HL, Schnizlein-Bick CT, Weiden M, Valentine F, Wheat J, Day RB, et al. Measurement of antiretroviral drugs in the lungs of HIV-infected patients. HIV Ther 2010;4:247–51. https://doi.org/10.2217/hiu.10.5.

[17] Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf 2017;16:411–9. https://doi.org/10.1080/14740338.2017.1293168.

[18] Pilkington V, Hill A, Hughes S, Nwokolo N, Ponziani A. How safe is TDF/FC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. J Virus Erad 2018;4:215–24. https://doi.org/10.22036/jve.2018.30312-5.

[19] Hernández-Díaz S, Bateman BT, Braub L, Zhu Y, Mogun H, Fischer M, et al. Safety of tenofovir disoproxil fumarate for pregnant women facing the coronavirus disease 2019 pandemic. Am J Epidemiol 2021;200:2339–49. https://doi.org/10.1093/aje/kwab109.

[20] Yao X, Ye F, Zhang M, Cui H, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71:732–9. https://doi.org/10.1093/cid/ciaa237.

[21] Mehra MR, Desai RS, Ruchatka F, Patel AN. RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for COVID-19 infection: a multinational registry analysis. Lancet 2020. https://doi.org/10.1016/S2468-2667(20)31180-6.

[22] Seet RCS, Quek AML, Ooi DSQ, Sengupta S, Lakshminarasappa SR, Koo CY, et al. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial. Int J Infect Dis 2021;106:314–22. https://doi.org/10.1016/j.ijid.2021.04.015.
[23] Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases SA. Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis 2021;73:e2005–15. https://doi.org/10.1093/cid/ciaa1198.

[24] Del Amo J, Polo R, Moreno S, Martínez E, Cabello A, Iríbarren J, et al. Tenofovir disoproxil fumarate and severity of COVID-19 in people with HIV infection. 29th conference on retroviruses and opportunistic infections (CROI). 2022. https://doi.org/10.1097/QAD.00000000000003372. Abstract 00867.

[25] Muñoz-Mateos B, Buti M, Fernández I, Hernández M, Bernal VFD. Tenofovir reduces the severity of COVID-19 infection in chronic hepatitis B patients. J Hepatol 2021;75:S746–7. https://doi.org/10.1097/QAD.000000000000337225.

[26] Park S, Yu K, Kim Y, Kim S, Kim E, Kim S, et al. Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets. mBio 2020;11:e01114-20. https://doi.org/10.1128/mBio.01114-20.

[27] Parienti JJ, Prazuck T, Peyro-Saint-Paul L, Fournier A, Valentin C, Brucato S, et al. Effect of tenofovir disoproxil fumarate and emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: a pilot, randomized, open-label phase 2 trial. EClinicalMedicine 2021;38:100993. https://doi.org/10.1016/j.eclinm.2021.100993.

[28] Feng J, Bilello J, Rahassis D, Gordon C, Tchesnokov E, Perry J, et al. NRTIs tenofovir, TAF, TDF, and FTC are inactive against SARS-CoV-2. 18th European AIDS Conference (EACS), October 27-30, 2021. Virtual & London, United Kingdom.

[29] Embi PJ, Levy ME, Naleway AL, Patel P, Gaglani M, Natarajan K, et al. Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. MMWR Morb Mortal Wkly Rep 2021;70:1553–9. https://doi.org/10.15585/mmwr.mm7044e3.

[30] López MG, Chiner-Oms A, García de Viedma D, Ruiz-Rodriguez P, Bracho MA, Cancino-Munoz I, et al. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant. Nat Genet 2021;53:1405–14. https://doi.org/10.1038/s41588-021-00936-6.

[31] Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med 2020;173:623–31. https://doi.org/10.7326/M20-4207.